Genentech BioOncology Co-pay Card
At Genentech BioOncology, we are committed to helping patients access the therapies they need. We've made some changes to the Genentech BioOncology Co-pay Card that will help simplify patient enrollment.
How does this card work?
There is now one card for all of our Genentech cancer therapies, with one set of eligibility criteria, one set of benefits and one number to call.
The card reduces out-of-pocket costs for your eligible patients, regardless of income.* Out-of-pocket costs are defined as the co-pay, co-insurance or deductible for your patients' therapy. This must clearly be defined on the Explanation of Benefits when submitted.
- *If your patient's annual household income is >$100,000, the card limit is reduced. See "How much does the card cover?" below for details.
Find out if your patients are eligible†
| Eligible | Not Eligible |
|---|---|
|
|
- † Patients taking most Genentech cancer therapies must meet certain medical criteria to be eligible.
What is the patient's responsibility?
| Patient's responsibility | 20% (but no more than $100) of the out-of-pocket costs for each Genentech cancer treatment (per prescription or infusion) |
| Card covers | At least 80% of the out-of-pocket costs for each Genentech cancer treatment (per prescription or infusion) |
| Card limit | Up to $24,000 per year*† |
- *Patients who make a household income of >$100,000 per year have a limit of $9,000.Patients only need to provide a verbal statement to verify their income when they enroll. Proof of documentation at a later date may be required.
- †Some patients may be on more than one Genentech BioOncology therapy, and the benefits above apply to each product individually. Coverage eligibility for multiple products is determined at enrollment.
Enrolling patients
If you want to enroll your patients or have any questions, call 855-MYCOPAY (855-692-6729) from 9 am - 8 pm ET, Monday through Friday or visit copayassistancenow.com For additional co-pay materials, including cards and brochures, contact your BioOncology sales representative.
What about my RITUXAN patients
who are not eligible for the Genentech BioOncology Co-pay Card?
We develop therapies for serious or life-threatening medical conditions and we believe they should be accessible for the patients who need them. At Rituxan® Access Solutions, we are here to help find a way for you to get RITUXAN to your patients, regardless of their ability to pay for it. A Rituxan Access Solutions Specialist can refer ineligible patients to an independent, non-profit organization (INO)‡ that may be able to help. Uninsured patients may be able to get free therapy through GATCF.
Contact Rituxan Access Solutions via phone at
(888) 249-4918 6 am-5 pm PT, Monday-Friday
Or visit our website at RituxanAccessSolutions.com
- ‡Genentech and Biogen Idec do not influence or control the operations of these INOs, but Rituxan Access Solutions can assist patients in navigating the process of seeking co-pay assistance by making an appropriate referral based on a patient's diagnosis and by assisting with the application process. We cannot guarantee co-pay assistance once a patient has been referred by Rituxan Access Solutions. The INOs to which we refer patients each have their own criteria for patient eligibility, including financial eligibility.
Indications
RITUXAN® (Rituximab) is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
- Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC)
RITUXAN is not recommended for use in patients with severe, active infections.
Important Safety Information
WARNING: FATAL INFUSION REACTIONS, TUMOR LYSIS SYNDROME (TLS), SEVERE MUCOCUTANEOUS REACTIONS, and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
Infusion Reactions: RITUXAN administration can result in serious, including fatal, infusion reactions. Deaths within 24 hours of RITUXAN infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Carefully monitor patients during infusions. Discontinue RITUXAN infusion and provide medical treatment for Grade 3 or 4 infusion reactions.
Tumor Lysis Syndrome (TLS): Acute renal failure requiring dialysis with instances of fatal outcome can occur in the setting of TLS following treatment of non-Hodgkin's lymphoma (NHL) with RITUXAN monotherapy.
Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving RITUXAN.
Progressive Multifocal Leukoencephalopathy (PML): JC virus infection resulting in PML and death can occur in patients receiving RITUXAN.
Warnings and Precautions
RITUXAN has also been associated with other serious and/or fatal adverse reactions. These include
- hepatitis B reactivation with fulminant hepatitis; hepatic failure resulting in death
- serious, including fatal, bacterial, fungal, and new or reactivated viral infections
- cardiovascular events, including serious or life-threatening cardiac arrhythmias
- severe, including fatal, renal toxicity
- abdominal pain, bowel obstruction and perforation, in some cases leading to death, can occur in patients receiving RITUXAN in combination with chemotherapy
Additional Important Safety Information
- The most frequent Grade 3 or 4 adverse reactions observed in NHL were cytopenias, including lymphopenia. The most common adverse reactions of RITUXAN (incidence ≥25%) observed in clinical trials of patients with NHL were infusion reactions, fever, lymphopenia, chills, infection, and asthenia. The incidence of infusion reactions was highest during the first infusion (77%) and decreased with each subsequent infusion. These infusion reactions typically resolved with slowing or interruption of the infusion and with supportive care
- The most common adverse reactions of RITUXAN (incidence ≥25%) observed in clinical trials of patients with CLL were infusion reactions and neutropenia. Infusion-related adverse reactions occurring during or within 24 hours of the start of infusion included nausea, pyrexia, chills, hypotension, vomiting, and dyspnea
- Most CLL patients treated with R-FC experienced at least one Grade 3 or 4 adverse reaction. The Grade 3 or 4 adverse reactions observed more frequently with R-FC compared with FC alone were neutropenia, leukopenia, febrile neutropenia, thrombocytopenia, infusion reactions, pancytopenia, hypotension, and hepatitis B
- In clinical trials, CLL patients 70 years of age or older who received R-FC had more Grade 3 and 4 adverse reactions compared with younger CLL patients who received the same treatment
For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.
Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.